Glucagon-Like Peptide-1 Protects β-Cells Against Apoptosis by Increasing the Activity of an Igf-2/Igf-1 Receptor Autocrine Loop
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The gluco-incretin hormones glucagon-like peptide (GLP)-1 and gastric inhibitory peptide (GIP) protect β-cells against cytokine-induced apoptosis. Their action is initiated by binding to specific receptors that activate the cAMP signaling pathway, but the downstream events are not fully elucidated. Here we searched for mechanisms that may underlie this protective effect. RESEARCH DESIGN AND METHODS: We performed comparative transcriptomic analysis of islets from control and GipR−/−;Glp-1-R−/− mice, which have increased sensitivity to cytokine-induced apoptosis. We found that IGF-1 receptor expression was markedly reduced in the mutant islets. Because the IGF-1 receptor signaling pathway is known for its antiapoptotic effect, we explored the relationship between gluco-incretin action, IGF-1 receptor expression and signaling, and apoptosis. RESULTS: We found that GLP-1 robustly stimulated IGF-1 receptor expression and Akt phosphorylation and that increased Akt phosphorylation was dependent on IGF-1 but not insulin receptor expression. We demonstrated that GLP-1–induced Akt phosphorylation required active secretion, indicating the presence of an autocrine activation mechanism; we showed that activation of IGF-1 receptor signaling was dependent on the secretion of IGF-2. We demonstrated, both in MIN6 cell line and primary β-cells, that reducing IGF-1 receptor or IGF-2 expression or neutralizing secreted IGF-2 suppressed GLP-1–induced protection against apoptosis. CONCLUSIONS: An IGF-2/IGF-1 receptor autocrine loop operates in β-cells. GLP-1 increases its activity by augmenting IGF-1 receptor expression and by stimulating secretion; this mechanism is required for GLP-1–induced protection against apoptosis. These findings may lead to novel ways of preventing β-cell loss in the pathogenesis of diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Replication of Genome-Wide Association Signals in UK Samples Reveals Risk Loci for Type 2 Diabetes
Zeggini, E., Weedon, M. N., Lindgren, C. M., Frayling, T. M., Elliott, K. S., Lango, H., Timpson, N. J., Perry, J. R. B., Rayner, N. W., Freathy, R. M., et al. (2007) · Science · doi:10.1126/science.1142364 · Cited by 2,194
Islet cell failure in type 2 diabetes
Prentki, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29103 · Cited by 1,690
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Self-citationNielsen, J., Christiansen, J., Lykke-Andersen, J., Johnsen, A. H., Wewer, U. M., & Nielsen, F. C. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1262 · Cited by 721
Vilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021873 · Cited by 528 · cited 1×
“Because there is a link between feeding and GLP-1 secretion (33), reduced susceptibility to apoptosis may also participate in the increased -cell mass observed in obesity.”
BackgroundcAMP-GEFII is a direct target of cAMP in regulated exocytosis
Ozaki, N., Shibasaki, T., Kashima, Y., Miki, T., Takahashi, K., Ueno, H., Sunaga, Y., Yano, H., Matsuura, Y., Iwanaga, T., et al. (2000) · Nature Cell Biology · doi:10.1038/35041046 · Cited by 481 · cited 1×
“Increases in cAMP levels, for instance, as stimulated by GLP-1 or GIP action, potentiate glucose-stimulated insulin secretion by both protein kinase A (PKA)-dependent and -independent mechanisms (9); they also stimulate gene transcription through PKAdependent phosphorylation of the transcription factor CREB (cAMP-resp…”
BackgroundButeau, J., Roduit, R., Susini, S., & Prentki, M. (1999) · Diabetologia · doi:10.1007/s001250051238 · Cited by 413 · cited 1×
“GLP-1 has previously been demonstrated to protect -cells against apoptosis by increasing IRS-2 expression (14,16), PI 3-kinase activity (30), Akt phosphorylation (31) and Foxo1 phosphorylation, and nuclear exclusion (32).”
BackgroundTranscription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic β-cell mass
Buteau, J., Spatz, M. L., & Accili, D. (2006) · Diabetes · doi:10.2337/db05-0825 · Cited by 178 · cited 1×
“GLP-1 has previously been demonstrated to protect -cells against apoptosis by increasing IRS-2 expression (14,16), PI 3-kinase activity (30), Akt phosphorylation (31) and Foxo1 phosphorylation, and nuclear exclusion (32).”
BackgroundKlinger, S., Poussin, C., Debril, M.-B., Dolci, W., Halban, P. A., & Thorens, B. (2008) · Diabetes · doi:10.2337/db07-1414 · Cited by 86 · cited 3×
“Western blot analysis was performed as described (21) with antibodies diluted in Tris-buffered saline–5% nonfat dry milk (1/500 dilution for IGF-1R, IR and phosphorylated Akt [Thr308 and Ser473], and phosphorylated Bad and 1/1,000 for actin, total Akt, total Bad, and IGF-2) and revealed using horseradish peroxidase–co…”
MethodResultInfluentialSelf-citation
Cited by
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
“The biosynthesis, secretion and subsequent activation of the IGF-2/IGF-1R autocrine loop is significantly enhanced by the presence of glutamine, and has been reported to protect β-cells against apoptosis, and increases β-cell glucose competence (20, 98, 99).”
BackgroundAnti-obesogenic and antidiabetic effects of plants and mushrooms
Martel, J., Ojcius, D. M., Chang, C.-J., Lin, C.-S., Lu, C.-C., Ko, Y.-F., Tseng, S.-F., Lai, H.-C., & Young, J. D. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.142 · Cited by 266
The insulin secretory granule as a signaling hub
Suckale, J., & Solimena, M. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.06.003 · Cited by 201
Bouzakri, K., Plomgaard, P., Berney, T., Donath, M. Y., Pedersen, B. K., & Halban, P. A. (2011) · Diabetes · doi:10.2337/db10-1178 · Cited by 122
Metadata
- Authors
- Cornu, M., Yang, J.-Y., Jaccard, E., Poussin, C., Widmann, C., & Thorens, B.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2009-04-28
- Volume
- 58
- Issue
- 8
- Pages
- 1816-1825
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2141915016
- Cited by
- 146
- References
- 11
- FWCI
- 14.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.